Ignite Creation Date:
2024-05-05 @ 11:53 AM
Last Modification Date:
2024-10-26 @ 9:15 AM
Study NCT ID:
NCT00163215
Status:
COMPLETED
Last Update Posted:
2012-12-19
First Post:
2005-09-09
Brief Title:
Growth Retardation In Children With Special Pathological Conditions Or Disease
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
Evolution Of Growth Rate In Children Suffering From A Disease Associated With Growth Retardation and Treated By Genotonorm A Pilot Study
Status:
COMPLETED
Status Verified Date:
2012-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To show an increase in annual growth rate 3 years after Visit 2 Annual growth rate in standard deviation SD after 3 years will be compared to growth rate before the start of GH treatment
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None